Genmab — September 2020
-
-
Tusinde tal kkjoel.
-
Abstract fra Phase 2 innovaTV 204 Study på ESMO fremlægges Mandag d. 21 kl. 17.04
-
God morgen.
-
og selvfølgelig godmorgen og god weekend til jer alle
-
LBA32 - Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study https://twitter.com/bertrandbio/status/1307081654733803520?s=21
-
1258O - Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC $GMAB $JNJ #ESMO20
ORR 43% in unselected pop., 57% in post-osimertinib pop https://twitter.com/bertrandbio/status/1307080230083985411?s=21 -
Dr Park presented on amivantamab (nee JNJ-372) at #ASCO20. Tox is not as much of a barrier here (disclosure, I have been involved with development). There is a rather unique infusion reaction on D1, but few dose reductions or interruptions. ORR 36%, PFS 8.3 months https://twitter.com/jbauml/status/1307001526288814080?s=21
-
I am optimistic about amivantamab here - I think it has the most favorable AE profile https://twitter.com/jbauml/status/1307037126748524544?s=21
-
-
-
ØU: "Genmab
Genmab kan levere Blockbuster-medicin på samlebåndGenmabs udviklingsprogrammer begynder nu at levere de forventede resultater. Det styrker investorernes tro på, at Genmab kan levere blockbustere på samlebånd".
-
Kursmålet hæves til 2.800.
-
De 2.800 er på 12 måneders sigt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind